Frequency, Age, Gender Distribution, and Seasonal Variation of Guillain-Barré Syndrome in a Province of Pakistan: A Retrospective Study

Prevalance of Guillain-Barre Syndrome


  • Mian Ayaz ul Haq Department of Neurology, Hayatabad Medical Complex, Peshawar, Pakistan
  • Danish Nabi Department of Neurology, Hayatabad Medical Complex, Peshawar, Pakistan
  • Muhammad Owais Khan Department of Neurology, Hayatabad Medical Complex, Peshawar, Pakistan
  • Rifat Ullah Department of Neurology, Hayatabad Medical Complex, Peshawar, Pakistan
  • Muhammad Junaid Department of Neurology, Hayatabad Medical Complex, Peshawar, Pakistan
  • Hafiza Mariam Nasarullah Department of Neurology, Hayatabad Medical Complex, Peshawar, Pakistan



Guillain Barre Syndrome, Subtypes, Electrodiagnosis


Characterized by the sudden onset of muscle weakness, Guillain-Barré Syndrome (GBS) is a rare autoimmune disorder which can progress to paralysis. GBS has different subtypes based on the clinical and electrophysiological characteristics, including acute inflammatory demyelinating polyradiculoneuropathy (AIDP), axonal GBS (AMAN and AMSAN), and Miller Fisher Syndrome (MFS). Objective: To study frequency of the disease in Khyber Pakhtunkhwa. Methods:  In this retrospective study, medical records of 39 patients diagnosed with GBS at Lady Reading Hospital Peshawar, Pakistan, were analyzed to determine the prevalence of GBS subtypes in the country. Results: The results showed that the most prevalent subtype of GBS was AMAN, accounting for 59% of cases, followed by AMSAN at 25.6%, and AIDP at 15.3%. The axonal variety made up 84.6% of the total GBS cases in this study. On average, the patients with AMSAN were 39.2 years old, while patients with AMAN and AIDP were relatively younger, with mean ages of 30 and 28 years, respectively. There was a male predominance in all subtypes except for AIDP, which showed equal distribution. Conclusions: These findings provide valuable information on the distribution of GBS subtypes in Peshawar, Pakistan, which may have implications for the diagnosis and management of GBS in the country. Additionally, the study's results can contribute to the global understanding of GBS epidemiology and may help improve the diagnosis and treatment of GBS patients worldwide.


Willison HJ, Jacobs BC, van Doorn PA. Guillain-barre syndrome. The Lancet. 2016 Aug; 388(10045): 717-27. doi: 10.1016/S0140-6736(16)00339-1. DOI:

Wakerley BR, Yuki N. Infectious and noninfectious triggers in Guillain–Barré syndrome. Expert review of clinical immunology. 2013 Jul; 9(7): 627-39. doi: 10.1586/1744666X.2013.811119. DOI:

Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain–Barré syndrome. Cochrane Database Systematic Reviews. 2014 Sep; 2014(9): CD002063. doi: 10.1002/14651858.CD002063.pub6. DOI:

Verboon C, Van Doorn PA, Jacobs BC. Treatment dilemmas in Guillain-Barré syndrome. Journal of Neurology, Neurosurgery & Psychiatry. 2017 Apr; 88(4): 346-52. doi: 10.1136/jnnp-2016-314862. DOI:

Jacobs BC, Rothbarth PH, Van der Meché FG, Herbrink P, Schmitz PI, De Klerk MA, et al. The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study. Neurology. 1998 Oct; 51(4): 1110-5. doi: 10.1212/WNL.51.4.1110. DOI:

Kuwabara S and Yuki N. Axonal Guillain-Barré syndrome: concepts and controversies. The Lancet Neurology. 2013 Dec; 12(12): 1180-8. doi: 10.1016/S1474-4422(13)70215-1. DOI:

Doets AY, Verboon C, Van Den Berg B, Harbo T, Cornblath DR, Willison HJ, et al. Regional variation of Guillain-Barré syndrome. Brain. 2018 Oct; 141(10): 2866-77.

Cao-Lormeau VM, Blake A, Mons S, Lastère S, Roche C, Vanhomwegen J, et al. Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. The Lancet. 2016 Apr; 387(10027): 1531-9. doi: 10.1016/S0140-6736(16)00562-6. DOI:

McGrogan A, Madle GC, Seaman HE, de Vries CS. The epidemiology of Guillain–Barré syndrome worldwide: a systematic literature review. Neuroepidemiology. 2009; 32(2): 150- 63. doi: 10.1159/000184748. DOI:

Shahrizaila N, Lehmann HC, Kuwabara S. Guillain–Barré syndrome. Lancet. 2021 Mar; 397(10280): 1214-28. doi: 10.1016/S0140-6736(21)00517-1. DOI:

Hughes RA and Cornblath DR. Guillain–Barré syndrome. Lancet. 2005 Nov; 366(9497): 1653-66. doi: 10.1016/S0140-6736(05)67665-9. DOI:

Kaida K and Kusunoki S. Antibodies to gangliosides and ganglioside complexes in Guillain–Barré syndrome and Fisher syndrome: mini-review. Journal of neuroimmunology. 2010 Jun; 223(1-2): 5-12. doi: 10.1016/j.jneuroim.2010.02.001. DOI:

Willison HJ and Yuki N. Peripheral neuropathies and anti-glycolipid antibodies. Brain. 2002 Dec;125(12):2591-2625. doi: 10.1093/brain/awf272. DOI:

Van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. The Lancet Neurology. 2008 Oct; 7(10): 939-50. doi: 10.1016/S1474-4422(08)70215-1. DOI:

Van der Meché FG, Van Doorn PA. Guillain‐Barre syndrome and chronic inflammatory demyelinating polyneuropathy: immune mechanisms and update on current therapies. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society. 1995 May; 37(S1): 14-31. doi: 10.1002/ana.410370704. DOI:

Walgaard C, Lingsma HF, Ruts L, Van Doorn PA, Steyerberg EW, Jacobs BC. Early recognition of poor prognosis in Guillain-Barre syndrome. Neurology. 2011 Mar; 76(11): 968-75. doi: 10.1212/WNL.0b013e3182104407. DOI:

van Koningsveld R, Steyerberg EW, Hughes RA, Swan AV, van Doorn PA, Jacobs BC. A clinical prognostic scoring system for Guillain-Barré syndrome. The Lancet Neurology. 2007 Jul; 6(7): 589-94. doi: 10.1016/S1474-4422(07)70130-8. DOI:

Jacobs BC, van den Berg B, Verboon C, Chavada G, Cornblath DR, Gorson KC, et al. International Guillain‐Barré Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain‐Barré syndrome. Journal of the Peripheral Nervous System. 2017 Jun; 22(2): 68-76. doi: 10.1111/jns.12209. DOI:

Al Maawali SM, Al Shibani AY, Nadeem AS, Al-Salti AM. Guillain–Barre syndrome: demographics, clinical features, and outcome in a single tertiary care hospital, Oman. Neurosciences Journal. 2020 Oct; 25(5): 369-74. doi: 10.17712/nsj.2020.5.20200057. DOI:

Hadden RD, Cornblath DR, Hughes RA, Zielasek J, Hartung HP, Toyka KV, Swan AV, Plasma Exchange/Sandoglobulin Guillain‐Barré Syndrome Trial Group. Electrophysiological classification of Guillain‐Barré syndrome: clinical associations and outcome. Annals of Neurology. 1998 Nov; 44(5): 780-8. doi: 10.1002/ana.410440512. DOI:

Chowdhury D and Arora A. Axonal Guillain–Barré syndrome: a critical review. Acta neurologica scandinavica. 2001 May; 103(5): 267-77. doi: 10.1034/j.1600-0404.2001.103005267.x. DOI:

Ansari B, Basiri K, Derakhshan Y, Kadkhodaei F, Okhovat AA. Epidemiology and clinical features of Guillain-Barre syndrome in Isfahan, Iran. Advanced Biomedical Research. 2018; 7. doi: 10.4103/abr.abr_50_17. DOI:

Koga M, Kusunoki S, Kaida K, Uehara R, Nakamura Y, Kohriyama T, Kanda T. Nationwide survey of patients in Japan with Bickerstaff brainstem encephalitis: epidemiological and clinical characteristics. Journal of Neurology, Neurosurgery & Psychiatry. 2012 Dec; 83(12): 1210-5. doi: 10.1136/jnnp-2012-303060 DOI:



DOI: 10.54393/pjhs.v4i03.565
Published: 2023-03-31

How to Cite

Ayaz ul Haq, M. ., Nabi, D., Khan, M. O. ., Ullah, R., Junaid, M. ., & Nasarullah, H. M. (2023). Frequency, Age, Gender Distribution, and Seasonal Variation of Guillain-Barré Syndrome in a Province of Pakistan: A Retrospective Study: Prevalance of Guillain-Barre Syndrome. Pakistan Journal of Health Sciences, 4(03), 207–210.



Original Article